Abbott Laboratories (NYSE:ABT – Get Free Report) updated its third quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 1.380-1.46 for the period, compared to the consensus EPS estimate of 1.420. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2026 guidance to 5.450-5.60 EPS.
Abbott Laboratories Stock Performance
Abbott Laboratories stock opened at $98.81 on Friday. The firm has a market capitalization of $172.11 billion, a P/E ratio of 27.68, a P/E/G ratio of 1.54 and a beta of 0.61. The stock has a fifty day moving average price of $89.56 and a two-hundred day moving average price of $102.18. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.
Abbott Laboratories Announces Dividend
Wall Street Analyst Weigh In
Several brokerages have issued reports on ABT. Piper Sandler restated an “overweight” rating and issued a $115.00 price target on shares of Abbott Laboratories in a report on Monday, June 22nd. JPMorgan Chase & Co. dropped their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Raymond James Financial lowered their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Royal Bank Of Canada dropped their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Robert W. Baird initiated coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $117.61.
Read Our Latest Stock Report on Abbott Laboratories
Insider Transactions at Abbott Laboratories
In related news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by company insiders.
Key Abbott Laboratories News
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Abbott reported Q2 adjusted EPS of $1.31, topping estimates, while revenue rose 13% year over year and sales growth was broad-based across medical devices, diagnostics, and nutrition. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58, which suggests management is seeing better profitability trends than Wall Street expected. Abbott raises 2026 profit forecast on heart device strength
- Positive Sentiment: Investor sentiment improved because demand for Abbott’s heart devices and diagnostics appears to be strengthening, especially after management pointed to a better second-half outlook and continued momentum in those segments. Why Abbott Stock Jumped Today
- Neutral Sentiment: Abbott continues to trade well above its recent 50-day average, but it remains below its 200-day average, so the longer-term trend is still mixed despite the earnings-driven rebound.
- Negative Sentiment: Some headlines note that the stock had been under pressure earlier this year, and while the latest results helped, concerns about the broader trend and valuation are not fully gone. Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?
Hedge Funds Weigh In On Abbott Laboratories
Several hedge funds and other institutional investors have recently modified their holdings of the business. Brighton Jones LLC boosted its stake in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares in the last quarter. United Bank grew its holdings in shares of Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC increased its position in Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its stake in shares of Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after buying an additional 292,547 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Has Broadcom Become Too Expensive for Its AI Story?
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
